Biomarin Pharmaceutical Inc.
Sector: Manufacturing
Industry: Pharmaceutical Products
62.60
0.66
(1.07%)
Volume:
317,112
52 week range:
52.93 - 94.85
Market Cap:
11.817B
Company Description:
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.